Functional Magnetic Resonance Imaging and Applications in Dermatology.

As a noninvasive imaging modality able to show the dynamic changes in neurologic activity, functional magnetic resonance imaging has revolutionized the ability to both map and further understand the functional regions of the brain. Current applications range from neurosurgical planning to an enormous variety of investigational applications across many diverse specialties. The main purpose of this article is to provide a foundational understanding of how functional magnetic resonance imaging is being used in research by outlining the underlying basic science, specific methods, and direct investigational and clinical applications. In addition, the use of functional magnetic resonance imaging in current dermatological research, especially in relation to studies concerning the skin‒brain axis, is explicitly addressed. This article also touches on the advantages and limitations concerning functional magnetic resonance imaging in comparison with other similar techniques.

Amelioration of visual deficits and visual system pathology after mild TBI via the cannabinoid Type-2 receptor inverse agonism of raloxifene.

Visual deficits after traumatic brain injury (TBI) are common, but interventions that limit the post-trauma impairments have not been identified. We have found that treatment with the cannabinoid type-2 receptor (CB2) inverse agonist SMM-189 for 2 weeks after closed-head blast TBI greatly attenuates the visual deficits and retinal pathology this otherwise produces in mice, by modulating the deleterious role of microglia in the injury process after trauma. SMM-189, however, has not yet been approved for human use. Raloxifene is an FDA-approved estrogen receptor drug that is used to treat osteoporosis, but it was recently found to also show noteworthy CB2 inverse agonism. In the current studies, we found that a high pressure air blast in the absence of raloxifene treatment yields deficits in visual acuity and contrast sensitivity, reductions in the A-wave and B-wave of the scotopic electroretinogram (ERG), light aversion, and increased pupil constriction to light. Raloxifene delivered daily for two weeks after blast at 5-10 mg/kg mitigates or eliminates these abnormalities (with the higher dose generally more effective). This functional rescue with raloxifene is accompanied by a biasing of microglia from the harmful M1 to the helpful M2 state, and reductions in retinal, optic nerve, and oculomotor nucleus pathology. We also found that raloxifene treatment is still effective even when delayed until 48 h after TBI, and that raloxifene benefit appears attributable to its CB2 inverse agonism rather than its estrogenic actions. Our studies show raloxifene is effective in treating visual injury after brain and/or eye trauma, and they provide basis for phase-2 efficacy testing in human clinical trials.

Implementation of a patient-assisted teledermatology model in the Veteran Health Administration.

Owing to the inherently visual nature of the field of dermatology, advances in imaging and communication technology have resulted in wide-spread application of teledermatology since its introduction in the mid-1990s. In the last 20 years, studies have repetitively shown that teledermatology provides effective and efficient quality care for patients. It also increases access to underserved patients and reduces traveling costs, wait times, and unnecessary referrals. In this letter the authors seek to analyze implementation of a direct patient to dermatologist model in a Veteran Health Administration (VHA) patient population, referred to as patient-assisted teledermatology. This population is largely over the age of 65 and a significant portion are either without internet or have the minimum technology necessary to participate in the studied model. Owing to these observations and personal experiences, the authors found the implementation process of a patient-assisted model to be challenging in this population.